Advertisement
Advertisement

Indicator

Free Access

Pay per View

Partial Free Access

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Platelet function testing: From bench to bedside

DOI: http://dx.doi.org/10.1160/TH10-10-0660
Issue: 2011: 106/2 (Aug) pp. 185-387
Pages: 363-370

Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion

A systematic review and meta-analysis

Online Supplementary Material

See also Editorial by Goto

F. Dentali (1), M. Gianni (2), A. Squizzato (1), W. Ageno (1), L. Castiglioni (1), L. Maroni (1), E. M. Hylek (3), A. M. Grandi (1), E. Cazzani (2), A. Venco (1), L. Guasti (1)

(1) Department of Clinical Medicine, University of Insubria, Varese, Italy; (2) Department of Cardiology, Hospital of Tradate, Varese, Italy; (3) Department of Medicine, Research Unit

Summary

Statins have important pleiotropic effects and have been shown to reduce vascular inflammation. Some evidence suggests that statins may have a role in the primary prevention of atrial fibrillation (AF), whereas little is know on the role of statins in patients with existing AF. We performed a meta-analysis of the literature to assess the effect of statins on the recurrence of AF after electrical cardioversion or ablation. MEDLINE and EMBASE databases were searched up to January 2010. Relative risks (RR) and 95% confidence intervals (CIs) were then calculated and pooled using a random-effects model. Statistical heterogeneity was evaluated through the use of I2 statistics. Sixteen studies were included in our systematic review. Statins did not reduce the risk of AF recurrence after ablation (four studies including 750 patients; RR, 1.04; 95% CI, 0.85–1.28, p=0.71; I2 = 34%). Conversely, the use of statins was associated with a significantly reduced risk of AF recurrence after electrical cardioversion (12 studies including 1790 patients; RR, 0.78; 95% CI, 0.67–0.90, p=0.0003; I2 = 34%). This reduction was not statistically significant when the analysis was restricted to randomised controlled trials (RCTs) only (five studies, 458 patients, RR, 0.76; 95% CI, 0.48–1.20). In conclusion, statins may lower the risk of AF recurrence after electrical cardioversion, but not ablation. However, this finding should be considered with caution, and larger RCTs are warranted to confirm our preliminary results.

Keywords

Atrial fibrillation, statins

DOI

http://dx.doi.org/10.1160/TH10-10-0660

You may also be interested in...

1.

Robert D. McBane1, David O. Hodge2, Waldemar E. Wysokinski1

Thromb Haemost 2008 99 5: 951-955

http://dx.doi.org/10.1160/TH07-12-0734

2.

T. Duning1, P. Kirchhof2, S. Knecht1

Nervenheilkunde 2008 27 3: 175-186

3.

Online Supplementary Material

Michael Hughes1, Gregory Y. H. Lip1,2, on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care

Thromb Haemost 2008 99 2: 295-304

http://dx.doi.org/10.1160/TH07-08-0508